Modality
Gene Therapy
MOA
TNFi
Target
IL-17A
Pathway
Complement
T2D
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
Apr 2021
→ Mar 2030
Phase 2Current
NCT07787274
1,907 pts·T2D
2021-04→2030-03·Active
1,907 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-013.9y awayPh3 Readout· T2D
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2/3
Active
Catalysts
Ph3 Readout
2030-03-01 · 3.9y away
T2D
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07787274 | Phase 2/3 | T2D | Active | 1907 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A |